Article Text

Download PDFPDF
A 2-Protein Signature Predicting Clinical Outcome in High-Grade Serous Ovarian Cancer
  1. Chengjuan Jin, PhD, MD*,
  2. Yingfeng Xue, PhD, MD,
  3. Yingwei Li, PhD, MD*,
  4. Hualei Bu, PhD, MD*,
  5. Hongfeng Yu, PhD, MD,
  6. Tao Zhang, MD§,
  7. Zhiwei Zhang, PhD, MD*,
  8. Shi Yan, PhD, MD*,
  9. Nan Lu, PhD, MD and
  10. Beihua Kong, PhD, MD*
  1. * Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan;
  2. Department of Gynecology, Zoucheng People's Hospital, Zoucheng, Shandong;
  3. Department of Obstetrics and Gynecology, Zhenjiang First People's Hospital, Zhenjiang, Jiangsu;
  4. § Zhejiang Provincial Center for Disease Control and Prevention, Binjiang District, Hangzhou, Zhejiang; and
  5. Institute of Diagnostics, School of Medicine, Shandong University, Jinan, PR China.
  1. Address correspondence and reprint requests to B. Kong, Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, 107 Wenhua Xi Rd, Jinan 250012, PR China. E-mail: qlkongbeihua{at}yahoo.com, kongbeihua{at}sdu.edu.cn; N. Lu, Institute of Diagnostics, School of Medicine, Shandong University, 44 Wenhua Xi Rd, Jinan 250012, PR China. E-mail: lunan0501{at}163.com.

Abstract

Objective High-grade serous ovarian cancer (HGSOC) accounts for approximately 70% deaths in ovarian cancer. The overall survival (OS) of HGSOC is poor and still remains a clinical challenge. High-grade serous ovarian cancer can be divided into 4 molecular subtypes. The prognosis of different molecular subtypes is still unclear. We aimed to investigate the prognostic values of immunohistochemistry-based different molecular subtypes in patients with HGSOC.

Methods We analyzed the protein expression of representative biomarkers (CXCL11, HMGA2, and MUC16) of 3 different molecular subtypes in 110 formalin-fixed, paraffin-embedded HGSOC by tissue microarrays.

Results High CXCL11 expression predicted worse OS, not disease-free survival (DFS; P = 0.028 for OS, P = 0.191 for DFS). High HMGA2 expression predicted worse OS and DFS (P = 0.037 for OS, P = 0.021 for DFS). MUC16 expression was not associated with OS or DFS (P = 0.919 for OS, P = 0.517 for DFS). Multivariate regression analysis showed that CXCL11 combined with HMGA2 signature was an independent predictor for OS and DFS in patients with HGSOC.

Conclusions CXCL11 combined with HMGA2 signature was a clinically applicable prognostic model that could precisely predict an HGSOC patient's OS and tumor recurrence. This model could serve as an important tool for risk assessment of HGSOC prognosis.

  • CXCL11
  • HMGA2
  • MUC16
  • HGSOC
  • Clinical outcome

Statistics from Altmetric.com

Footnotes

  • The authors declare no conflicts of interest.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.